Title: Prevalence of Myopathy in Type 2 Diabetes Mellitus
Authors: Dr Srikantan Sreedharan Pillai, Bhurkunde Rajesh Baba Rao
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.201
Abstract
Background: Type 2 diabetes accounts for about 90% cases of diabetes and is expected to affect almost 8% of the world population by 2030.The incidence of Type 2 Diabetes is on the rise in developing countries. Type 2 Diabetes is associated with both microvascular and macrovascular complications. Diabetic skeletal muscle disease or myopathy, a much less studied complication of poorly controlled diabetes, is also a common clinical condition characterised by a lower muscle mass and an overall reduced physical activity. Hence this study was undertaken to determine the affection of muscle in Type 2 Diabetes.
Objectives
1. To find out the prevalence of myopathy in type 2 diabetes
2. To find out the association of Myopathy with the duration of diabetes as well as the type of treatment.
Materials and Methods: 150 patients with type 2 diabetes was taken up for the study. They were assessed for the presence of Myopathy based on history, clinical examination and lab investigations.
Results: The prevalence of myopathy was found to be 17.3%. 60.9% of diabetic patients with myopathywere having duration more than 20 years. 83.3% of Diabetic patients with Myopathy were on oral hypoglycemics. Among the muscle groups the proximal muscles of the lower limb were maximally involved .followed by distal muscles of the lower limb
Conclusions: From our study the prevalence of Myopathy was 17.3%. .There was a significant association of myopathy with Duration of Diabetes more than 20yrs.In addition there was a significant association of Myopathy with Oral Hypoglycemic Agents. Proximal muscles of the lower limb was the predominant muscle group involved.
References
1. Chinnery PF, Muscle Diseases.In; Goldman L,Schafer AI eds, Goldmans Cecil Medicine,24th ed.Philadelphia.PA; Elsevier Saunders; 2011;chap 429
2. Shaw JE, SicreeRA, Zimmet PZ .Global estimates for the prevalence of diabetes for 2010 and 2030. Diabetes. Res .Clin.Pract 2010;87;4-14.
3. Brownlee M.The pathobiology of diabetic complications.A Unifying mechanism. Diabetes2005;54(6);1615-1625
4. Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration Frontiers in .Physiol 2013;4;371
5. Vignaud A, Ramond F. Hourde C et al. Diabetes provides an unfavourable environment for muscle mss and function after muscle injury in mice. Pathobiology 2007;74;291-300
6. Peterson JM. BrynerRW. Always SE. Satellite cell proliferation is reduced in muscles of obese zucker rats but restored with loading .Am.J. Physiol 2008;295;521-528
7. Krause MP, Moradi J Nissar AA. et al. Inhibition of plasminogen activator inhibitor1 restores skeletal muscle regeneration in untreated type1 diabetic mice .Diabetes 2011;60;1964-1972
8. AndersenH, Gjerstad MD, Jakobsen J Atrophy of foot muscles A measure of Diabetic neuropathy. Diabetes care 2004;27;2382-2385.
9. Andersen H, Poulsen PL, Mogensen CE .et a l Isokinetic muscle strength in long term IDDM patients in relation to diabetic complications. Diabetes 1996;45;440-445
10. Andersen H Schmitz O, Nielsen S Decre-ased isometric muscle strength after acute hyperglycemia in type 1 diabetic patients. Diabetic. Med.2005;22;1401-1407
11. Stenholm S, Harkenen T, Sainio P. Long term changes in hand grip strength in men and women accounting the effect of right censoring due to death, J.Gerontol A Biolsci.Med.Sci.2012;67(10);1068-1074
12. KapurS, BrunetJA, McKendry RJ. Diabetic muscle infarction case report and review J Rheumatol 2004;31;190-194
13. First Medical Dept, Danube University Krems, Vienna Austria. Creatine Kinase elevation, Lactacidemia and Metabolic Myopathy in adult patients with diabetes mellitus. Endocrine practice 2012;18(3) 387-393.
14. Brady K,Huang Johnny U, Monu V Diabetic Myopathy MRI patterns and Current trends.AJR 2010;195;198-20.